Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07VZV
|
|||
| Former ID |
DIB004109
|
|||
| Drug Name |
N-0861
|
|||
| Synonyms |
WRC-0006; WRC-0007
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cardiac disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Discontinued in Phase 3 | [1] | |
| Company |
Aderis Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H17N5
|
|||
| Canonical SMILES |
CN1C=NC2=C(N=CN=C21)NC3CC4CCC3C4
|
|||
| InChI |
1S/C13H17N5/c1-18-7-16-11-12(14-6-15-13(11)18)17-10-5-8-2-3-9(10)4-8/h6-10H,2-5H2,1H3,(H,14,15,17)/t8-,9+,10-/m1/s1
|
|||
| InChIKey |
MTQYIGCUBBMQCJ-KXUCPTDWSA-N
|
|||
| CAS Number |
CAS 141696-90-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A1 receptor (ADORA1) | Target Info | Antagonist | [2] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| cAMP signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Adenosine P1 receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Nucleotide GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003285) | |||
| REF 2 | N-0861 selectively antagonizes adenosine A1 receptors in vivo. Eur J Pharmacol. 1992 May 27;216(1):9-16. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.